Non Small Cell Lung Cancer Clinical Trials in Aurora, Colorado

14 studies are recruiting for non small cell lung cancer in Aurora, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Aurora, Colorado
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prev…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Colorado Cancer Center ( Site 3268), Aurora, Colorado
    Locations
    93 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07513376 on ClinicalTrials.gov

  3. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Colorado - Aurora Cancer Center, Aurora, Colorado
    Locations
    49 in total
    Run by
    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

  4. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Colorado, Aurora, Colorado
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  5. Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

    This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery o…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Rocky Mountain Cancer Centers,LLP, Aurora, Colorado
    Locations
    87 in total
    Run by
    Pfizer

    See if you can join NCT07227298 on ClinicalTrials.gov

  6. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora, Colorado
    Locations
    38 in total
    Run by
    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

  7. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Colorado Health Hospital, Aurora, Colorado
    Locations
    33 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov

  8. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Colorado Cancer Center, Aurora, Colorado
    Locations
    38 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06343402 on ClinicalTrials.gov

  9. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Colorado Health, Aurora, Colorado
    Locations
    118 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07185997 on ClinicalTrials.gov

  10. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Colorado/Memorial, Aurora, Colorado
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  11. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Colorado Cancer Center, Aurora, Colorado
    Locations
    5 in total
    Run by
    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

  12. Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

    A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of th…

    Stage
    Not phased
    Ages
    18 to 85
    Site
    University of Colorado, Cancer Center, Aurora, Colorado
    Run by
    University of Colorado, Denver

    See if you can join NCT03042221 on ClinicalTrials.gov

  13. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Colorado Cancer Center, Aurora, Colorado
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Aurora, Colorado
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.